Key takeaways
- BPC-157 is a synthetic 15-amino-acid peptide. We found no paper, trial registry record or FDA list that uses the name PDA (21 Nov 2026); a 2017 patent describes arginine salts of BPC-157 and does not use the name either.
- The patent describes laboratory stability tests and experiments in cell and animal models. Those findings do not establish an effect in people or identify an unrelated sample.
- A 2025 systematic review of musculoskeletal research included 35 preclinical studies and one clinical study. BPC-157’s human evidence remains limited.
- FDA staff evaluated BPC-157 free base and acetate, not an identified PDA sample. Australia’s October 2026 Poisons Standard names BPC-157 in Schedule 4 and Appendix D.
01PDA and BPC-157 in one table
The comparison starts with a distinction between a name, a chemical form and a tested sample.
| Question | PDA name | BPC-157 |
|---|---|---|
| Identity | We found no paper, trial registry record or FDA list that uses the name (21 Nov 2026); a label does not verify a sample. | A synthetic peptide of 15 amino acids. [1] |
| Arginine salt | Whether a particular sample matches the patent’s salt is unverified. | A patent describes a BPC-157 arginine salt. [2] |
| Evidence | The patent’s experiments cannot be assigned to a sample without confirming its identity. | Research includes cell, animal and small human studies. [1, 3] |
| Regulatory documents | No FDA document we read names it (21 Nov 2026). | FDA’s compounding page and Australia’s Poisons Standard name BPC-157. [4, 5] |
The comparison is not a ranking. The evidence for a named peptide, the evidence for a salt form and the evidence about one sample answer different questions.
02What does the name PDA refer to?
If you searched “pda peptide”: we found no peer-reviewed paper, trial registry record or FDA list that uses the name “pentadeca arginate” or PDA (PubMed, ClinicalTrials.gov and FDA’s 503A list, 21 November 2026), and none that says what it contains. What a given vial holds is a question for its lab report, not its name.
FDA staff describe BPC-157 as a peptide of 15 amino acids. [1] Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. A peptide is a chain of amino acids; their order identifies the chain. A salt is a chemical form associated with another charged component. The associated component and the peptide chain are separate things to describe.
A 2017 US patent describes salts of BPC-157, called bepecin in that document, with basic amino acids, and prefers one with two arginines per peptide chain. [2] The patent does not use the name PDA, and it is not a laboratory report for any sample. More on the chain and research record: BPC-157 research guide.
03What does the patent describe?
The patent describes laboratory stability tests of a BPC-157 arginine salt and compares it with other forms. It also describes experiments using an arginine salt in cell and animal models. [2] Those are preclinical descriptions: cell work is T4 and animal work is T3 in this site’s evidence ladder. Neither establishes an effect in people.
The tests belong to the patent’s described material and conditions. Even if two samples are labelled with the same name, that does not show that they were made, tested or stored in the same way. A stability comparison in a laboratory also answers a different question from whether two substances have comparable effects or safety profiles in people.
The patent is a document from the inventor and applicant, not an independent test of a separate vial. We cannot assign its experiments to material called PDA without evidence that the material matches what was studied. A patent is not a regulator’s decision.
04What has BPC-157 research measured?
A 2025 systematic review of musculoskeletal research included 36 studies, of which 35 were preclinical and one was clinical. [3] That count applies to the studies selected for the review, not every BPC-157 publication. Its preclinical models cannot establish an outcome in people.
In a 2024 human pilot, Lee and colleagues studied 12 women using a questionnaire, without a control group. [1] This is small human observational evidence, T2. Without a control group, the study cannot separate an intervention’s contribution from other possible explanations. The study material has not been established as equivalent to material sold online, and the pilot does not settle how an arginine salt compares with another form.
Randomised BPC-157 data have appeared in conference abstracts that FDA staff summarised; we found no peer-reviewed randomised trial that gave BPC-157 to people (PubMed, design words with no publication-type filter, 21 November 2026). [1, 6] Small uncontrolled human studies and registered trials do exist. Study registration, publication and a result are separate steps.
FDA staff concluded that clinical safety information was insufficient to characterise the safety profile of the free base and acetate forms they evaluated. [1] That is a statement about the forms in the FDA review, not a separate assessment of an unverified PDA sample.
05What do the regulatory documents say?
United States. FDA’s compounding safety page places BPC-157 under substances whose nominations were withdrawn. Its entry retains concerns about compounded drugs containing BPC-157. [4] The entry says compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration”.
FDA staff evaluated BPC-157 free base and acetate and recommended against listing either; HHS records that the advisory committee voted in favour. HHS’s October 2026 draft compounding policy names BPC-157, and the Federal Register notice says the draft “is not binding”. [7]
Australia. The Poisons Standard October 2026 names BPC-157 in Schedule 4 and Appendix D, clause 5. [5]
United Kingdom. The emc medicines database returned no results for BPC-157 (21 November 2026); it is not the full UK register. BPC-157’s UK record, with its sources: BPC-157 in the UK.
06What can a lab report answer?
We do not know whether a particular material labelled PDA contains the peptide or salt described in the patent. A report can narrow that question only to the extent that it identifies the sample, describes the method and states what was actually measured.
Look for the sample and batch identifiers on the report, and whether they correspond to the material being described.
Check what the laboratory says it identified. A purity percentage alone does not establish which peptide produced the measured signal.
A result for peptide identity is not automatically a separate measurement of the associated salt component. Nor does identity alone establish sterility or human safety.
For a closer look at the fields, methods and limitations, see how to read a certificate of analysis. The question is not simply whether a document exists: it is what that document can support about that sample.
This is a plain-English summary of public documents checked on 21 November 2026. It is not legal or medical advice.